Loading... (0%)
About liver disease
GENFIT is a biopharmaceutical company at the forefront of developing therapeutic and diagnostic solutions to address high unmet patient needs...
Learn more
The NASH Education Program: An initiative by GENFIT
LEARN MORE
Elafibranor phase 3 study in NASH with fibrosis is currently recruiting patients all around the world.
LEARN MORE

Press releases
  • Data to be Presented at EASL 2017 Highlighting GENFIT’s Latest Progress in NASH Biomarker Diagnostics, Identifying Novel Compounds with Potent Antifibrotic Properties, and Illustrating the Opportunities in Anti-NASH Drug Combinations
    04/05/2017
  • GENFIT to Host a Series of KOL Meetings in NASH
    03/28/2017
  • GENFIT: The NASH Education Program™ – Inaugural Press Conference, Paris – March 9, 2017
    02/14/2017
  • GENFIT Initiates Paediatric NAFLD/NASH Program in Europe Further to the Approval of elafibranor’s Paediatric Investigation Plan by the EMA
    11/14/2016
  • GENFIT: FDA has officially cleared the IND to proceed with Phase II trial and evaluate elafibranor in PBC
    11/04/2016
Events